Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1995-06-06
1996-10-22
Kight, John
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
530300, 530326, 530327, 530328, 530329, 530330, 534 10, 534 14, 534 15, A61K 5100, C07K 200, C07F 500
Patent
active
055674089
ABSTRACT:
Peptides containing a biological-function domain which includes the sequence Tyr-Ile-Gly-Ser-Arg (YIGSR) and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in a variety of diseases and pathologic conditions, and particularly for diagnosis and treatment of thrombosis and other diseases and conditions.
REFERENCES:
patent: 4427646 (1984-01-01), Olexa et al.
patent: 4479930 (1984-10-01), Hnatowich
patent: 4668503 (1987-05-01), Hnatowich
patent: 4732864 (1988-03-01), Tolman
patent: 4822606 (1989-04-01), Snyderman et al.
patent: 4877868 (1989-10-01), Reno et al.
patent: 4986979 (1991-01-01), Morgan, Jr. et al.
patent: 5039662 (1991-08-01), Schasteen et al.
patent: 5078985 (1992-01-01), Rhodes
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5102990 (1992-04-01), Rhodes
patent: 5118791 (1992-06-01), Burnier et al.
patent: 5190920 (1993-03-01), Eyal et al.
patent: 5236903 (1993-08-01), Saiki et al.
patent: 5328840 (1994-07-01), Coller
patent: 5330911 (1994-07-01), Hubbell et al.
patent: 5371184 (1994-12-01), Rajagopalan et al.
patent: 5443815 (1995-08-01), Dean et al.
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5460785 (1995-10-01), Rhodes et al.
Sandrock, B., "Kinetics of I.V. Injected 1-131-Labeled Laminin-C.sub.1 -Fragmet in Normal and Tumor-Bearing Nude Mice," Proceedings of the AACR, vol. 30, Abstract No. 390 (1989).
Liotta, Lance A., "Laminin Receptors on Human Breast Carcinoma: Role in Invasion of the Extracellular Matrix", Understanding Breast Cancer: Clinical and Laboratory Concepts, Rich, N, et al (eds). pp. 87-97 (1983).
Zamora, P. O., et al., "A Second Tc-99m Binding Site In IgG. Is Related To Distadine Groups," J. Nucl. Med., vol. 33, No. 5, (1992), Abstract No. 86.
Swanson, D., et al "Laminin Peptide Fragments for Malignant Tumor Detection", Proc. of 40th Ann. Meet., Journal of Nuclear Medicine, vol. 34, No. 5, p. 231P (May 1993).
Buchanan, M. R., "Mechanisms of Pathogenesis of Arterial Thrombosis: Potential Sites of Inhibition by Therapeutic Compounds", Sem. Thrombosis and Hemostasis, vol. 14, pp. 33-40 (1988).
Hynes, R. O., "Integrins: Versatility, Modulation, and Signalling in Cell Adhesion", Cell, vol. 69, pp. 11-25 (1992).
Ill, Charles R., et al., "Adhesion of Platelets to Laminin in the Absence of Activation", J. of Cell Biol., vol. 99, pp. 2140-2145 (1984).
Imura, Yoshimi, et al., "Antithrombotic Properties of L-Cysteine . . . ",Blood, vol. 80, No. 5, pp. 1247-1253 (1992).
Knight, L. C., et al., "Thrombus Imaging with Tc-99m Synthetic Peptides Reactive with Activated Platelets", J. Nucl. Med., vol. 31, p. 757 (Abstract) (1990).
Shah, V. O., et al., "In Vitro Studies with the Platelet-Reactive Antibody 50H.19 and Its Fragments", Thrombosis Research, vol. 58, pp. 493-504 (1990).
Som, P., et al., "Radioimmunoimaging of Experimental Thrombi in Dogs Using Tc-99m Labeled Monoclonal Antibody Fragments Reactive with Human Platelets", J. Nucl. Med., vol. 27, pp. 1315-1320 (1986).
Sonnenberg, A., et al., "Isolation of Alpha6Betal Integrins from Platelets and Adherent Cells by Chromatography on Mouse Laminin Fragment E8 and Human Laminin Pepsin Frament", Exp Cell Res., vol. 197, pp. 234-244 (1991).
Tandon, N. M., et al., "Interactionof Human Platelets with Laminin and Identification of the 67 kDa Laminin Receptor on Platelets", Biochem J., vol. 274, pp. 535-542 (1991).
Yamada, K. M., et al., "Adhesive Recognition Sequences", J. Biol. Chem., vol. 266, pp. 2809-2812 (1992).
Pimm, M. V., et al., "In labelling of a branched polypeptide drug carrier with a poly(L-lysin) backbone,"Int'l J. Pharm., vol. 79 (1992) pp. 77-80.
Zamora, P. O., et al., "Lung Uptake of .sup.99m Tc-Laminin Peptide PA22-2 Is Decreased in Emphysema and Increased in Tumored Lung", Abstract, J. Nucl. Med., vol. 34, No. 5, (1993), Abstract No. 1133.
Babich et al (1993). Technetium -99m labeled hydra zino nicotinamide derivatized chemotactic peptide analog for imaging focal sites of bacterial infection. J. Nucl. Med., vol. 34, No. ll, pp. 1964-1974.
Zamora et al (1993). Biological distribution of 99m-Tc labeled YIGSR and IKVAV laminin peptides in rodents: 99m-Tc-IKVAV peptide localizes to the lungs. Biochim. Biophys. Acta., vol. 1182, No. 2, pp. 197-204.
Zamora et al (1992). Imidazdes as Well as Thioates in Proteins Bind Technetium -99m. Bioconjugate Chemstry, vol. 3, No. 6, pp. 493-498.
Murata et al (1989). Int. J. Biol. Macromol., vol. 11, No. 2, pp. 97-99. Inhibitory effect of a Synthetic polypeptide, poly(Tyr-Ile-Gly-Ser-Arg), on metastatic formation of malignant tumor cells.
Hegge David P.
Jones Dameron L.
Kight John
Peacock Deborah A.
RhoMed Incorporated
LandOfFree
YIGSR peptide radiopharmaceutical applications does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with YIGSR peptide radiopharmaceutical applications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and YIGSR peptide radiopharmaceutical applications will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2356587